レイノー病(Raynauds Disease)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Raynauds Disease Overview 7
Therapeutics Development 8
Pipeline Products for Raynauds Disease – Overview 8
Pipeline Products for Raynauds Disease – Comparative Analysis 9
Raynauds Disease – Therapeutics under Development by Companies 10
Raynauds Disease – Therapeutics under Investigation by Universities/Institutes 11
Raynauds Disease – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Raynauds Disease – Products under Development by Companies 15
Raynauds Disease – Products under Investigation by Universities/Institutes 16
Raynauds Disease – Companies Involved in Therapeutics Development 17
Allergan, Inc. 17
Apricus Biosciences, Inc. 18
Azevan Pharmaceuticals, Inc. 19
Bayer AG 20
Human Stem Cells Institute 21
Mezzion Pharma Co. Ltd. 22
Nippon Shinyaku Co., Ltd. 23
Teva Pharmaceutical Industries Limited 24
Raynauds Disease – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
alprostadil – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ELS-140 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MDT-012 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
onabotulinumtoxin A – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
riociguat – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
selexipag – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit Alpha 2 Adrenergic Receptor for Raynauds Disease – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SRX-251 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
udenafil – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Raynauds Disease – Recent Pipeline Updates 51
Raynauds Disease – Dormant Projects 66
Raynauds Disease – Discontinued Products 67
Raynauds Disease – Product Development Milestones 68
Featured News & Press Releases 68
Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa 68
Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud’s Phenomenon 68
Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa 69
Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum 70
May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud’s Phenomenon 70
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud’s Phenomenon 71
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa 71
Sep 22, 2010: FDA Guides Apricus Bio On RayVa’s Approvability For Raynaud’s Syndrome Secondary To Scleroderma 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74